Sector News

GSK sells meningitis vaccines to Pfizer

June 22, 2015
Life sciences
GlaxoSmithKline will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer to satisfy regulatory conditions for its asset-swap deal with Novartis.
 
The European Commission and other antitrust regulators were concerned because GSK acquired two rival meningitis vaccines – Menveo and Bexsero – from Novartis as part of the deal, which could have given the company too much power in the market.
 
Nimenrix and Mencevax are older vaccines that had combined sales of £34 million last year. The total value of the transaction with Pfizer is £82 million.
 
“Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need – the prevention of meningococcal disease across all ages,” says Susan Silbermann, president of Pfizer Vaccines.
 
“Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis – an uncommon but serious and sometimes fatal disease.”
 
Last year Pfizer purchased another meningitis vaccine, Baxter’s NeisVac-C, and had its own serogroup B meningococcal disease drug Trumenba approved.
 
The sale is expected to be completed by the end of the year.
 
By George Underwood
 
Source: Pharma Times

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach